Further Detail of Profit or Loss (Tables)

12 Months Ended

Dec. 31, 2021

Profit or loss [abstract]

Schedule of further detail of profit or loss

	For the year ended December 31
	2019			2020			2021
	Thousands USD			Thousands USD			Thousands USD
A. Research and development expenses, net
Payroll		4,672	(*)		4,849			14,604
Share-based payment expenses		162	(*)		1,682			14,238
Materials		1,001			940			2,764
Subcontractors		82			258			2,864
Patent registration		144			160			441
Depreciation		1,534			1,588			5,697
Rental fees and maintenance		197			173			559
Other		339			249			637
		8,131			9,899			41,804
Less – government grants		(49	)		(21	)		(118	)
		8,082			9,878			41,686
B. Sales and marketing expenses
Payroll		2,729			3,336			8,283
Share-based payment expenses		144			1,990			8,569
Marketing, advertising and commissions		1,808			577			4,053
Rental fees and maintenance		114			201			365
Travel abroad		317			235			749
Depreciation		212			223			318
Other		145			35			376
		5,469			6,597			22,713
C. General and administrative expenses
Payroll		872			1,377			2,880
Share-based payment expenses		155			16,837			6,974
Fees		22			22			33
Professional services		1,545			1,064			6,993
Office expenses		359			386			1,065
Travel abroad		37			44			461
Depreciation		78			76			210
Rental fees and maintenance		43			46			97
Other		159			435			931
		3,270			20,287			19,644
D. Finance income
Revaluation of liability in respect of government grants		58			75			25
Exchange rate differences		-			123			3,444
Revaluation of financial liabilities at fair value through profit or loss (**)		8,707			-			10,608
Bank interest and fees		-			248			3,832
		8,765			446			17,909
Finance expense
Exchange rate differences		151			-			-
Bank fees		14			28			70
Finance expense in respect of lease liability		425			390			237
Revaluation of financial liabilities at fair value through profit or loss (**)		-			12,825			-
Fundraising expenses		1,693			-			-
Revaluation of liability in respect of government grants		-			-			121
		2,283			13,243			428

(*) Reclassified.

(**) See Note 19 regarding financing transactions that included issuance of financial instruments accounted at fair value through profit and loss.